Home › All Companies › ALLO

Allogene Therapeutics, Inc. (ALLO)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-15

Key Insights

  • Allogene Therapeutics is conducting a $175 million public offering of 87.5 million shares of common stock at $2 per share, which could provide additional capital to fund the company's clinical trials and research and development.
  • The company has granted the underwriters a 30-day option to purchase up to an additional 13.125 million shares, which could increase the total proceeds from the offering.
  • Allogene plans to use the net proceeds from the offering for general corporate purposes, including funding clinical trials, research and development, and capital expenditures.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-04-13

Key Insights

  • Allogene announced positive interim results from its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL), with 58.3% of patients in the cema-cel arm achieving minimal residual disease (MRD) negativity compared to 16.7% in the observation arm.
  • Cema-cel was generally well-tolerated, with no serious adverse events related to treatment and no cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GvHD) observed.
  • The ALPHA3 trial is expected to enroll approximately 220 patients, with an interim EFS analysis planned for mid-2027 and the primary EFS analysis in mid-2028, which if positive could support a Biologics License Application (BLA) submission.
Sentiment: Positive Significance: 8/10
View Original Filing →
Current Report Filed: 2026-04-13

Key Insights

  • Allogene Therapeutics has suspended its common stock offering under the existing sales agreement, likely to focus on a new proposed underwritten public offering of its common stock.
  • The company has not provided any details about the proposed public offering, such as the size, timing or purpose, which creates some uncertainty for investors.
  • Suspension of the existing sales agreement and a new public offering could signal Allogene is seeking to raise additional capital, potentially for expansion, development or other corporate purposes.
Sentiment: Neutral Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-03-18

Key Insights

  • The reporting person, David D. Chang, who is the President and CEO of Allogene Therapeutics, Inc. (ALLO), sold 47,763 shares of common stock on March 16, 2026, likely to cover tax withholding obligations related to the vesting of restricted stock units.
  • Chang also holds a significant indirect beneficial ownership of Allogene's common stock, with 856,044 shares held in the RTC 2019 Trust and another 856,044 shares held in the JEC 2019 Trust, as well as an additional 1,201,108 shares held in the Chang 2006 Family Trust.
  • The sale of shares to cover tax obligations is a routine practice, but the continued significant indirect ownership by the CEO suggests a positive long-term outlook for the company.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-03-18

Key Insights

  • The reporting person, Benjamin Machinas Beneski, who is the SVP and Chief Technical Officer of Allogene Therapeutics, Inc. (ALLO), sold 4,835 shares of the company's common stock to cover tax withholding obligations related to the vesting of restricted stock units.
  • The shares were sold at a weighted average price of $2.47, which is within the range of $2.46 to $2.47 per share.
  • The reported transaction is a mandatory 'sell to cover' transaction to satisfy tax withholding obligations and does not represent a discretionary trade by the reporting person.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-02-04

Key Insights

  • Insider Arie Belldegrun has acquired a significant number of Allogene Therapeutics shares, indicating potential confidence in the company's future prospects.
  • Belldegrun owns shares directly as well as indirectly through various trusts and investment vehicles, suggesting a diversified ownership structure.
  • The granting of stock options and restricted stock units to Belldegrun further aligns his interests with those of Allogene Therapeutics shareholders.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-02-04

Key Insights

  • The reporting person, Zachary Roberts (EVP of R&D), sold 35,700 shares of Allogene Therapeutics, Inc. (ALLO) common stock at a weighted average price of $1.77 per share to cover tax withholding obligations related to the vesting of restricted stock units.
  • Roberts also received a new stock option grant for 718,763 shares with a strike price of $1.87, vesting over 4 years, and 203,307 restricted stock units that will vest over 4 years.
  • The insider selling, while mandatory to cover taxes, may indicate a cautious sentiment about the company's near-term prospects, though the new equity grants suggest a longer-term commitment to Allogene.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-02-04

Key Insights

  • The reporting person, Annie Yoshiyama, sold 4,167 shares of Allogene Therapeutics common stock at a weighted average price of $1.72 to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was mandated by the company's equity incentive plan and does not represent a discretionary trade.
  • The reporting person was granted 179,691 stock options with an exercise price of $1.87, which will vest over a 4-year period starting February 2, 2027. This indicates the company is providing long-term incentives to retain key talent.
  • The reporting person was also granted 50,827 restricted stock units, which will vest in 4 equal annual installments starting February 2, 2026. This further aligns the interests of the reporting person with those of shareholders.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-02-04

Key Insights

  • Douglas Earl Martin, SVP and General Counsel of Allogene Therapeutics, sold 22,900 shares of common stock on February 2, 2026, at an average price of $1.76 per share, potentially to cover tax withholding obligations related to the vesting of restricted stock units.
  • Martin also received a grant of 539,072 stock options and 152,480 restricted stock units on February 2, 2026, vesting over a four-year period, indicating the company's continued commitment to incentivize and retain its executive team.
  • The reported transaction appears to be a routine, non-discretionary sale to cover tax obligations, rather than a voluntary sale of shares, which may suggest the executive's continued confidence in the company's long-term prospects.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-02-04

Key Insights

  • The reporting person, Geoffrey M. Parker, who is the Chief Financial Officer of Allogene Therapeutics, Inc., sold 24,001 shares of the company's common stock to cover tax withholding obligations related to the vesting of restricted stock units.
  • The reporting person was granted 539,072 stock options and 152,480 restricted stock units, which will vest over time, indicating an alignment of the CFO's interests with those of the company and its shareholders.
  • The volume and timing of the stock sales suggest the reporting person's transactions were routine in nature and not indicative of any significant concerns about the company's prospects.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-02-04

Key Insights

  • The reporting person, David D. Chang, who is the President and CEO of Allogene Therapeutics, Inc. (ALLO), sold 95,269 shares of the company's common stock to cover tax withholding obligations in connection with the vesting of restricted stock units.
  • Chang also holds a significant number of shares in the company, both directly and indirectly through various trusts, indicating his alignment with the company's long-term success.
  • The company granted Chang additional stock options and restricted stock units, which vested over a multi-year period, further aligning his interests with those of shareholders.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-02-04

Key Insights

  • The reporting person, Benjamin Machinas Beneski, sold 7,549 shares of Allogene Therapeutics, Inc. (ALLO) common stock at an average price of $1.73 to cover tax withholding obligations related to the vesting of restricted stock units.
  • Beneski was granted 373,757 stock options and 105,720 restricted stock units, with the stock options vesting over a 4-year period and the RSUs vesting in 4 annual installments.
  • The insider selling was mandatory to cover tax obligations and not a discretionary trade, indicating no immediate concern about the company's outlook.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-01-23

Key Insights

  • The reporting person, Zachary Roberts, who is the EVP of R&D at Allogene Therapeutics, Inc. (ALLO), sold 26,269 shares of the company's common stock to cover tax withholding obligations related to the vesting of restricted stock units.
  • The sale was not a discretionary trade but rather a mandatory 'sell to cover' transaction as per the company's equity incentive plan, indicating the reporting person did not choose to sell the shares.
  • The reporting person still owns a significant 616,866 shares of the company's common stock following the reported transaction, suggesting continued confidence and investment in the company.
Sentiment: Neutral Significance: 4/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.